Hologic (NASDAQ:HOLX) jumps 7% premarket on light volume in reaction to its upward revision of Q4 guidance driven by strong sales of COVID-19 tests and Panther instruments.
The company forecasts revenue of $1,225M – $1,275M, up 54 – 60% from a year ago and up from its outlook of $925M – 1.025M provided in July.
The increased revenue is also expected to drive non-GAAP EPS significantly above prior guidance of $0.95 – 1.15.
https://seekingalpha.com/news/3613274-hologic-up-7-on-bullish-q4-outlook
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.